CN1623550A - Hydroxy progesterone caproate oral preparation and its use - Google Patents
Hydroxy progesterone caproate oral preparation and its use Download PDFInfo
- Publication number
- CN1623550A CN1623550A CNA2003101155957A CN200310115595A CN1623550A CN 1623550 A CN1623550 A CN 1623550A CN A2003101155957 A CNA2003101155957 A CN A2003101155957A CN 200310115595 A CN200310115595 A CN 200310115595A CN 1623550 A CN1623550 A CN 1623550A
- Authority
- CN
- China
- Prior art keywords
- hydroxyprogesterone caproate
- oral
- injection
- oral formulations
- bioavailability
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- DOMWKUIIPQCAJU-LJHIYBGHSA-N Hydroxyprogesterone caproate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)CCCCC)[C@@]1(C)CC2 DOMWKUIIPQCAJU-LJHIYBGHSA-N 0.000 title claims abstract description 50
- 229950000801 hydroxyprogesterone caproate Drugs 0.000 title claims description 51
- 238000002360 preparation method Methods 0.000 title claims description 14
- 239000003814 drug Substances 0.000 claims abstract description 29
- 239000002775 capsule Substances 0.000 claims abstract description 11
- 239000003826 tablet Substances 0.000 claims abstract description 5
- 239000007901 soft capsule Substances 0.000 claims abstract description 3
- 238000002347 injection Methods 0.000 claims description 26
- 239000007924 injection Substances 0.000 claims description 26
- 229940079593 drug Drugs 0.000 claims description 21
- 206010028980 Neoplasm Diseases 0.000 claims description 15
- 238000009472 formulation Methods 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 14
- 238000001647 drug administration Methods 0.000 claims description 8
- 239000000243 solution Substances 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 239000000375 suspending agent Substances 0.000 claims description 3
- 206010013908 Dysfunctional uterine bleeding Diseases 0.000 claims description 2
- 201000009273 Endometriosis Diseases 0.000 claims description 2
- 208000008899 Habitual abortion Diseases 0.000 claims description 2
- 208000019255 Menstrual disease Diseases 0.000 claims description 2
- -1 electuary Substances 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 239000006196 drop Substances 0.000 claims 1
- 230000002124 endocrine Effects 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 abstract description 6
- 208000026310 Breast neoplasm Diseases 0.000 abstract description 5
- 230000000694 effects Effects 0.000 abstract description 5
- 206010027514 Metrorrhagia Diseases 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 241000282472 Canis lupus familiaris Species 0.000 description 20
- 230000037396 body weight Effects 0.000 description 15
- 210000002784 stomach Anatomy 0.000 description 15
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 238000011160 research Methods 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000010255 intramuscular injection Methods 0.000 description 4
- 239000007927 intramuscular injection Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 210000002381 plasma Anatomy 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical group CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 229960004616 medroxyprogesterone Drugs 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- FRQMUZJSZHZSGN-HBNHAYAOSA-N medroxyprogesterone Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FRQMUZJSZHZSGN-HBNHAYAOSA-N 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- QRDYCDIUGUAUBZ-SRWWVFQWSA-N (7r,8s,9s,10r,13s,14s,17s)-17-acetyl-7-hydroxy-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one Chemical compound C([C@H]1O)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 QRDYCDIUGUAUBZ-SRWWVFQWSA-N 0.000 description 1
- DXNJBNPIVVOILB-QCGOMIHKSA-N (8s,9s,10r,13s,14s,17s)-17-acetyl-4-hydroxy-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one Chemical compound C1CC2=C(O)C(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 DXNJBNPIVVOILB-QCGOMIHKSA-N 0.000 description 1
- PWCLWZOSAFOXFL-UHPWKVKZSA-N (8s,9s,10r,13s,14s,17s)-17-acetyl-6-hydroxy-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one Chemical compound C1C(O)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 PWCLWZOSAFOXFL-UHPWKVKZSA-N 0.000 description 1
- DBPWSSGDRRHUNT-CEGNMAFCSA-N 17α-hydroxyprogesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 DBPWSSGDRRHUNT-CEGNMAFCSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229960002899 hydroxyprogesterone Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 208000009146 rhinoscleroma Diseases 0.000 description 1
- 239000007779 soft material Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
An orally taken medicine of hyproval-PA in the form of tablet, capsule, soft capsule, instant particles, etc for treating breast cancer and functional metrorrhagia is disclosed. its advantages are high biologic utilization rate and high curative effect.
Description
Technical field
The present invention relates to a kind of oral formulations and purposes of medicine.The oral formulations and the purposes that specifically contain hydroxyprogesterone caproate.
Technical background
Hydroxyprogesterone caproate (Hydroxyprogesterone Caproates) is that China's version pharmacopeia in 2000 is received the standard drug of planting.Indication is the treatment habitual abortion, menoxenia, endometriosis, dysfunctional uterine hemorrhage etc.Dosage form is the oily injection agent, and using method is intramuscular injection, 1-2 time weekly, and each 0.25-0.5g (250mg/ props up).Medicine stores in local deposits after the intramuscular injection, slowly absorb, and the performance long-acting, oil preparation is suitable to above indication.More than remove in addition, bibliographical information the otherwise purposes of hydroxyprogesterone caproate.Cheng Zhao contract quotation road intramuscular injection for treating advanced breast cancer in 1991, inject every day 1 time, each 0.5g, administration time 30 to 519 days (" cancer " 1991.6.491), Zhang Tingmei in 1996 have reported the dyscrasia of the pregnant hydroxyl ketone treatment of intramuscular injection caproic acid patients with advanced cancer, improve patient's quality of life.Inject each 0.5g (" Kweiyang medicine " 1996.2.96) every day.As mentioned above, hydroxyprogesterone caproate is an Oily preparation, and the injection back slowly absorbs, and in the local deposits storage, life-time service easily produces scleroma in the injection site, brings painful and influences to patient and use.To tumour patient is arranged, treatment time reaches several years especially, uses inconvenient.The development oral formulations replaces drug administration by injection to need.
Summary of the invention
The purpose of this invention is to provide the hydroxyprogesterone caproate oral formulations, replace ejection preparation to be used for the disease of existing clinical treatment and the indication of bibliographical information.The research oral formulations will make things convenient for patient's treatment, make oral hydroxyprogesterone caproate become commonly used, convenient, effective and safe drug.The present invention finds that first hydroxyprogesterone caproate oral formulations and injecting drug use have identical drug action, invention is to finish by bioavailability and drug action after the research oral preparation drug administration, thereby it is good to find that oral formulations absorbs, and has blood drug level close with drug administration by injection and pharmacologically actives such as identical antitumor action, the quality of making the life better.Oral administration is easy to use, safe, effective, can replace drug administration by injection.Invention has been carried out the absorption (bioavailability) and the pharmacodynamic study of hydroxyprogesterone caproate by experiment.The research of absorption portion: with the medicament contg in the high-performance liquid chromatogram determination blood plasma.Laboratory animal is mice and Canis familiaris L..The oral formulations of research has tablet, capsule, solution etc.Preparations such as tablet, capsule, solution adopt the conventional method preparation.Mice 0.25,0.5,1,2,4 at lumbar injection and after irritating stomach, 6h get hematometry drug plasma content, Canis familiaris L. intravenous injection and oral after get hematometry drug plasma content.Calculate area under medicine-time graph (AUC) then.(AUC behind the AUC/ drug administration by injection behind the oral administration) * 100%=bioavailability).Oral formulations such as tablet, capsule, solution absorb well at the oral hydroxyprogesterone caproate of mice and Canis familiaris L., and bioavailability reaches 85-90%.The research of drug effect part: compared the tumor-inhibiting action of irritating the harmonization of the stomach lumbar injection at mouse breast cancer EMT, experimental result shows, irritates harmonization of the stomach lumbar injection hydroxyprogesterone caproate the anti-tumor effect of mouse breast cancer basic identical (P＞0.05) has been observed oral administration to improving the effect of patients with advanced cancer life quality at 10 routine patients with advanced cancer.The effect of the therapeutical effect of oral hydroxyprogesterone caproate and bibliographical information drug administration by injection is basic identical.
The specific embodiment
Embodiment 1: assay method high-performance liquid chromatogram determination hydroxyprogesterone caproate, Waters490 chromatograph C18 post is measured wavelength 240nm, mobile phase: methanol: water=85: 15, flow velocity 1ml/ branch, sample introduction 20 μ l, sample disposal: hydroxyprogesterone caproate in the ether extraction blood plasma, interior mark medroxyprogesterone, the response rate 85%, the standard curve range of linearity: 0.1,0.2,0.4,0.8,1.0 μ g,, coefficient R=0.9998.Minimum dfetectable quantity 0.02 μ g.
Embodiment 2: the bioavailability Kunming mouse of hydroxyprogesterone caproate capsule behind mouse stomach, body weight 25-30 gram, per 3 is to get the blood point time, lumbar injection and filling stomach 200mg/kg hydroxyprogesterone caproate, got hematometry hydroxyprogesterone caproate concentration, and calculated area under the drug-time curve (AUC) and bioavailability in 0,0.25,0.5,1,2,4,6 hour after administration.The bioavailability of hydroxyprogesterone caproate capsule behind mouse stomach is 84.8%.
The blood drug level of injection of table 1. mouse peritoneal and filling stomach hydroxyprogesterone caproate
Time behind the medicine (h) and drug level (μ g/ml)
Route of administration AUC
0.25 0.5 1 2 4 6 (μg/ml/h)
Lumbar injection 1.23 1.16 0.87 0.56 0.42 0.28 2.37
Irritate stomach 0.82 1.02 0.78 0.50 0.33 0.22 2.01
Bioavailability=filling stomach AUC/ lumbar injection AUC * 100%=2.01/2.37=84.8%
Embodiment 3: the hydroxyprogesterone caproate tablet is in Canis familiaris L. oral bioavailability hydroxyprogesterone caproate tablet formulation and technology: hydroxyprogesterone caproate 250g, starch 120g, microcrystalline Cellulose 120g, magnesium stearate 10g.With preceding four kinds of mixings, cross 40 mesh sieve secondaries, 50% ethanol system soft material, the wet grain of the 16 mesh sieve systems of crossing, 60 ℃ of aeration-dryings.Granulate, granulating adds magnesium stearate, mixing, tabletting.Than lattice Canis familiaris L. body weight 8-10kg, dosage 100mg/kg, intravenously administrable is for slowly injecting 10 fens kinds, and oral administration is for to put into medicine in the 100ml meat soup, and Canis familiaris L. ate up at 2-3 minute.After administration 0,0.25,0.5,1,2,4, get hematometry hydroxyprogesterone caproate concentration during 6h, calculate area under the drug-time curve (AUC) and bioavailability.The oral hydroxyprogesterone caproate post-absorption of Canis familiaris L. is good, and bioavailability is 90.9% (table 2).
The blood drug level and the bioavailability of the oral hydroxyprogesterone caproate sheet of table 2. Canis familiaris L.
Time behind the medicine (h) and drug level (μ g/ml)
Route of administration AUC
0 0.25 0.5 1 2 4 6 (μg/ml/h)
Intravenous injection 1.16 0.58 0.43 0.24 0.22 0.13 0.09 1.31
Irritate stomach 0. 0.67 0.58 0.27 0.20 0.11 0.08 1.19
Bioavailability=oral AUC/ lumbar injection AUC * 100%=1.19/1.31=90.8%
Bioavailability hydroxyprogesterone caproate oil preparation prescription and the technology of embodiment 4 hydroxyprogesterone caproate oil preparationes (soft capsule) after Canis familiaris L. is oral: available from Huaihai Pharmaceuticla Factory, Shanghai's injection oil preparation, 250mg/ml.Than lattice Canis familiaris L. body weight 8-10kg, overnight fasting, dosage 100mg/kg body weight according to method experiment among the embodiment 2, is calculated bioavailability.The oral hydroxyprogesterone caproate tablet of Canis familiaris L. bioavailability is 89.5%.
Embodiment 5 hydroxyprogesterone caproate suspension agent are in bioavailability hydroxyprogesterone caproate suspension agent prescription and technology after Canis familiaris L. is oral: hydroxyprogesterone caproate 250g 95% ethanol heating dissolving fully, add 1/2 amount distilled water, and volatile fraction ethanol, the fine little element of methylate is made suspension.Than lattice Canis familiaris L. body weight 8-10kg, overnight fasting is pressed the administration of 100mg/kg body weight with the hydroxyprogesterone caproate suspension, according to method experiment among the embodiment 2, calculates bioavailability.The oral hydroxyprogesterone caproate tablet of Canis familiaris L. bioavailability is 86.7%.
Bioavailability hydroxyprogesterone caproate capsule prescription and the technology of embodiment 6 hydroxyprogesterone caproate capsules after Canis familiaris L. is oral: hydroxyprogesterone caproate 250g, starch 125g.Mixing is crossed 40 mesh sieve secondaries, and is encapsulated.Than lattice Canis familiaris L. body weight 8-10kg, overnight fasting, hydroxyprogesterone caproate capsule are pressed the administration of 100mg/kg body weight.According to method experiment among the embodiment 2, calculate bioavailability.The oral hydroxyprogesterone caproate tablet of Canis familiaris L. bioavailability is 88.5%.
Embodiment 7 hydroxyprogesterone caproates and medroxyprogesterone compound preparation bioavailability prescription and the technology after Canis familiaris L. is oral: hydroxyprogesterone caproate 250g, medroxyprogesterone 250g, starch 250g.Mixing is crossed 40 mesh sieve secondaries, and is encapsulated.Than lattice Canis familiaris L. body weight 8-10kg, overnight fasting, hydroxyprogesterone caproate capsule are pressed the administration of 100mg/kg body weight.According to method experiment among the embodiment 2, calculate bioavailability.The oral hydroxyprogesterone caproate tablet of Canis familiaris L. bioavailability is 85.1%.
Embodiment 8 irritates the tumor-inhibiting action Kunming mouse of harmonization of the stomach lumbar injection hydroxyprogesterone caproate, and body weight 19-21g is female.Animal model: mouse breast cancer, getting 0.2ml tumor kind, to be seeded in mice left fore axillary fossa subcutaneous.Inoculate beginning administration in back 24 hours, got tumor and weigh in the 10th day.Experiment is established matched group, is irritated stomach group, lumbar injection group.Dosage 100,150,200mg/kg.Medicine preparation: solvent is DMSO, quantity of solvent 0.1ml/ Mus, regimen be per 2 days once, connect and give 8 days.Experimental result shows, irritates harmonization of the stomach lumbar injection hydroxyprogesterone caproate to the anti-tumor effect of mouse breast cancer basic identical (P＞0.05) (table 3).
Table 3. is irritated the tumor-inhibiting action of harmonization of the stomach lumbar injection hydroxyprogesterone caproate
The number of animals body weight
The heavy tumour inhibiting rate of group tumor
(mg/kg) beginning begins last (g) (%) at last
Matched group 10 10 20.2 28.3 1.1 0
Irritate the stomach group
100 10 10 20.9 27.7 0.67 40.2*
150 10 10 20.9 28.5 0.60 46.4*
200 10 10 20.1 27.9 0.49 56.3*
Lumbar injection
100 10 10 20.9 28.8 0.63 43.8
150 10 10 20.9 27.8 0.61 45.5
200 10 10 20.1 27.8 0.51 54.5
Tumour inhibiting rate (%)=matched group tumor weight-experimental group tumor weight/matched group tumor heavy * 100%
*: compare P＞0.05 with lumbar injection.
The research patients with advanced cancer that embodiment 9 the improves the patients with advanced cancer life quality totally 10 examples research of receiving treatment.Man's 7 examples, women 3 examples, pulmonary carcinoma 6 examples, colon cancer 2 examples, gastric cancer 2 examples.Age 45-75 year.Bone transferrer 3 examples are arranged, and the whole body situation is all at the KSP index below 60.Medicine and method: delalutin tablet 500mg, once a day, logotype 30 days was a course of treatment.Observe it to patient's life quality improvement effect.Therapeutic evaluation: observe treatment front and back hepatic and renal function, the variation of appetite, body weight, pain and mental status.The result shows that the appetite that has after all patient's medications in various degree increases, and every day, food-intake increased that the person accounts for 73% more than 3 liang.4 routine patient body weights increase more than the 0.5kg, and 3 examples keep stable, and body weight continues to alleviate pain during the 3 routine medications: apparent alleviating after 60% patient's medication.Average 3-6 days begin onset after the medication, do not see untoward reaction, and the infringement of Liver and kidney merit is observed at the end.The basic identical Zhang Yanmei of the effect of the therapeutical effect of oral hydroxyprogesterone caproate and bibliographical information drug administration by injection (" Kweiyang medicine " 1996.2.96).
Claims (4)
1. relate to hydroxyprogesterone caproate oral formulations and uses thereof, it is good to it is characterized in that oral formulations absorbs, and with injection identical drug action is arranged, safe in utilization, convenient, can replace drug administration by injection.
2. the hydroxyprogesterone caproate oral formulations comprises that all enter gastral preparation, as tablet, capsule, soft capsule, powder, electuary, solution, suspension agent, drop etc.
3. according to right 1,2, the disease when its special card is used for the medication of the existing non-oral way of hydroxyprogesterone caproate is as habitual abortion, menoxenia, endometriosis, dysfunctional uterine hemorrhage, endocrine relies on related neoplasms treatment, the dyscrasia that diseases such as tumor cause.
4. according to right 1,2 described features, the compound preparation of hydroxyprogesterone caproate oral formulations and other chemical compound groups.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2003101155957A CN1623550A (en) | 2003-12-04 | 2003-12-04 | Hydroxy progesterone caproate oral preparation and its use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2003101155957A CN1623550A (en) | 2003-12-04 | 2003-12-04 | Hydroxy progesterone caproate oral preparation and its use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1623550A true CN1623550A (en) | 2005-06-08 |
Family
ID=34760503
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2003101155957A Pending CN1623550A (en) | 2003-12-04 | 2003-12-04 | Hydroxy progesterone caproate oral preparation and its use |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1623550A (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20140064819A (en) * | 2011-07-28 | 2014-05-28 | 리포신 인코포레이티드 | 17-hydroxyprogesterone ester-containing oral compositions and related methods |
| US9375437B2 (en) | 2010-06-18 | 2016-06-28 | Lipocine Inc. | Progesterone containing oral dosage forms and kits |
| CN107847506A (en) * | 2015-06-22 | 2018-03-27 | 来普卡公司 | Orally administered composition and correlation technique containing 17 Gestageno Gadors |
| CN112656801A (en) * | 2020-12-17 | 2021-04-16 | 深圳埃格林医药有限公司 | Use of progestagens in the treatment of cytokine release syndrome |
| CN113559107A (en) * | 2020-04-28 | 2021-10-29 | 深圳埃格林医药有限公司 | Application of progestogen in preparing medicine for inhibiting cell factor storm |
| WO2022117004A1 (en) * | 2020-12-01 | 2022-06-09 | 深圳埃格林医药有限公司 | Treatment method for interstitial pneumonia |
| WO2022188850A1 (en) * | 2021-03-11 | 2022-09-15 | 深圳埃格林医药有限公司 | Anti-tumor combined preparation comprising hydroxyprogesterone caproate and use thereof |
| CN115463217A (en) * | 2021-06-11 | 2022-12-13 | 深圳埃格林医药有限公司 | Application of hydroxyprogesterone caproate in enhancing tumor treatment effect |
| CN116077416A (en) * | 2021-11-05 | 2023-05-09 | 深圳埃格林医药有限公司 | Novel oral preparation containing progestogen and preparation method and application thereof |
-
2003
- 2003-12-04 CN CNA2003101155957A patent/CN1623550A/en active Pending
Cited By (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9375437B2 (en) | 2010-06-18 | 2016-06-28 | Lipocine Inc. | Progesterone containing oral dosage forms and kits |
| CN108514545A (en) * | 2011-07-28 | 2018-09-11 | 来普卡公司 | Include the Orally administered composition and correlation technique of 17- Gestageno Gadors |
| EP2736515A4 (en) * | 2011-07-28 | 2014-12-24 | Lipocine Inc | 17-hydroxyprogesterone ester-containing oral compositions and related methods |
| EP3763360A1 (en) * | 2011-07-28 | 2021-01-13 | Lipocine Inc. | 17-hydroxyprogesterone ester-containing oral compositions and related methods |
| US8951996B2 (en) | 2011-07-28 | 2015-02-10 | Lipocine Inc. | 17-hydroxyprogesterone ester-containing oral compositions and related methods |
| US9358298B2 (en) | 2011-07-28 | 2016-06-07 | Lipocine Inc. | 17-hydroxyprogesterone ester containing oral compositions and related methods |
| US9358299B2 (en) | 2011-07-28 | 2016-06-07 | Lipocine Inc | 17-hydroxyprogesterone ester-containing oral compositions and related methods |
| US9364547B2 (en) | 2011-07-28 | 2016-06-14 | Lipocine Inc. | 17-hydroxyprogesterone ester containing oral compositions and related methods |
| CN103826640A (en) * | 2011-07-28 | 2014-05-28 | 来普卡公司 | 17-hydroxyprogesterone ester-containing oral compositions and related methods |
| US9399069B2 (en) | 2011-07-28 | 2016-07-26 | Lipocine Inc. | 17-Hydroxyprogesterone ester containing oral compositions and related methods |
| AU2012286620B2 (en) * | 2011-07-28 | 2017-08-24 | Lipocine Inc. | 17-hydroxyprogesterone ester-containing oral compositions and related methods |
| JP2017193554A (en) * | 2011-07-28 | 2017-10-26 | リポカイン インコーポレーテッド | Oral composition comprising 17-hydroxyprogesterone ester and related method |
| US10709716B2 (en) | 2011-07-28 | 2020-07-14 | Lipocine Inc. | 17-hydroxyprogesterone ester-containing oral compositions and related methods |
| US10022384B2 (en) | 2011-07-28 | 2018-07-17 | Lipocine Inc. | 17-hydroxyprogesterone ester-containing oral compositions and related methods |
| KR20140064819A (en) * | 2011-07-28 | 2014-05-28 | 리포신 인코포레이티드 | 17-hydroxyprogesterone ester-containing oral compositions and related methods |
| US11471470B2 (en) | 2011-07-28 | 2022-10-18 | Lipocine Inc. | 17-hydroxyprogesterone ester-containing oral compositions and related methods |
| JP2014521660A (en) * | 2011-07-28 | 2014-08-28 | リポカイン インコーポレーテッド | Oral compositions containing 17-hydroxyprogesterone esters and related methods |
| CN107847506A (en) * | 2015-06-22 | 2018-03-27 | 来普卡公司 | Orally administered composition and correlation technique containing 17 Gestageno Gadors |
| US11590147B2 (en) | 2015-06-22 | 2023-02-28 | Lipocine Inc. | 17-hydroxyprogesterone ester-containing oral compositions and related methods |
| CN113559107B (en) * | 2020-04-28 | 2023-01-06 | 深圳埃格林医药有限公司 | Application of progestogen in preparing medicine for inhibiting cell factor storm |
| CN113559107A (en) * | 2020-04-28 | 2021-10-29 | 深圳埃格林医药有限公司 | Application of progestogen in preparing medicine for inhibiting cell factor storm |
| WO2022117004A1 (en) * | 2020-12-01 | 2022-06-09 | 深圳埃格林医药有限公司 | Treatment method for interstitial pneumonia |
| CN112656801A (en) * | 2020-12-17 | 2021-04-16 | 深圳埃格林医药有限公司 | Use of progestagens in the treatment of cytokine release syndrome |
| WO2022188850A1 (en) * | 2021-03-11 | 2022-09-15 | 深圳埃格林医药有限公司 | Anti-tumor combined preparation comprising hydroxyprogesterone caproate and use thereof |
| CN115068487A (en) * | 2021-03-11 | 2022-09-20 | 深圳埃格林医药有限公司 | Antitumor combined preparation containing hydroxyprogesterone caproate and application thereof |
| CN115068487B (en) * | 2021-03-11 | 2024-01-30 | 深圳埃格林医药有限公司 | Antitumor combination preparation containing hydroxyprogesterone caproate and application thereof |
| EP4338742A4 (en) * | 2021-06-11 | 2024-08-21 | Shenzhen Evergreen Therapeutics Co Ltd | Application of hydroxyprogesterone caproate in enhancing tumor treatment effect |
| CN115463217B (en) * | 2021-06-11 | 2024-03-12 | 深圳埃格林医药有限公司 | Application of hydroxyprogesterone caproate in enhancing tumor treatment effect |
| CN115463217A (en) * | 2021-06-11 | 2022-12-13 | 深圳埃格林医药有限公司 | Application of hydroxyprogesterone caproate in enhancing tumor treatment effect |
| CN116077416A (en) * | 2021-11-05 | 2023-05-09 | 深圳埃格林医药有限公司 | Novel oral preparation containing progestogen and preparation method and application thereof |
| WO2023078073A1 (en) * | 2021-11-05 | 2023-05-11 | 深圳埃格林医药有限公司 | Novel oral preparation containing progestogen, and preparation method and use |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107213149B (en) | Application of artemisinin derivatives in preparation of drugs for treating or assisting in treating autoimmune thyroid diseases | |
| CN1623550A (en) | Hydroxy progesterone caproate oral preparation and its use | |
| CN101502579B (en) | Chinese medicinal composition for treating digestive tumor and preparation method thereof | |
| CN1210289C (en) | Radde anemone rhizome extract and its prepn process and use | |
| CN102091111A (en) | Saussurea cataplasm and production method thereof | |
| CN101074255A (en) | Preparation of hemsleyadine-A and its use of preparing pharmaceutics against cancers | |
| CN104510853B (en) | A kind of Chinese medicinal effective-part composition for the treatment of dysmenorrhes and uses thereof | |
| CN101011545A (en) | Method for extracting effective sites group of smilax China root | |
| CN1883566A (en) | Anti-inflammation medicine and method for preparing same | |
| CN101209299B (en) | Chinese medicinal composition for treating pelvic inflammatory disease and extracting method thereof | |
| CN103006789A (en) | Preparation method of Glossy privet fruit and radix astragali sustained release preparations and product | |
| CN1179726C (en) | Application of naringin in preparing medicine for supporting treatment of SARS | |
| CN1217669C (en) | Naringin used in preparing medicine for curing acute and chronic bronchitis | |
| CN1141101C (en) | Chinese medicine for treating hepatitis B and its preparing process | |
| CN100348228C (en) | New use of powder for regulating liver and spleen and its active part | |
| CN1836665A (en) | Pharmaceutical uses of hesperidin or its composition | |
| CN101040891A (en) | Preparation method and application of tripterygium hypoglaucum alkaloids | |
| CN1193766C (en) | Gardenia total glycoside composite for curing hepatitis and its preparation method | |
| CN102813873A (en) | Traditional Chinese medicine composition for treating mental diseases, and preparation method, application and quality control thereof | |
| CN101468133A (en) | Pharmaceutical composition for treating inflammation of gynecology | |
| CN104739949A (en) | Composition for treating Parkinson disease and preparation method of composition | |
| CN116270632B (en) | A herba Achillea Wilsonianae alkaloid composition with detoxified effect and its preparation method | |
| CN102070700A (en) | Marsdenia tenacissima saponins H and preparation method and application thereof | |
| CN102631419B (en) | Medicine composition for treating gout, as well as preparation method and application of medicine composition | |
| CN101549032A (en) | Drug composition with the effect of anti-lung cancer and application in preparing anti-lung cancer drug |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: BEIJING JINGWEI YANKANG PHARMACEUTICALS RESEARCH Free format text: FORMER OWNER: ZHANG WEI; APPLICANT Effective date: 20070907 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20070907 Address after: 100070 Beijing city Fengtai District Haiying Road No. 3 Applicant after: Beijing Jingwei Yankang Pharmaceutical Research Institute Co., Ltd. Address before: 100850 C, gate 49, 27 Taiping Road, Beijing, Haidian District 1401, China Applicant before: Zhang Wei Co-applicant before: Zhang Zuoyun |
|
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |